Corvus Pharmaceuticals Inc. managed to price 4.7 million shares at $15, the low end of its desired range of $15 to $17, to raise $70.5 million and become just the eighth biopharma IPO of 2016, including two offerings of American depositary shares and one on the Australian Securities Exchange.